Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 443

First known gene transfer from plant to insect identified

“The results were surprising, but convincing, says Yannick Pauchet, a molecular entomologist also at the Max Planck Institute for Chemical Ecology. ” According to the data they provide, horizontal gene transfer is the most parsimonious explanation,” he says.

But how the whitefly managed to swipe a plant gene is unclear. One possibility, says Turlings, is that a virus served as an intermediate, shuttling genetic material from a plant into the whitefly genome.

As researchers s… See More.

Discovery that a whitefly uses a stolen plant gene to elude its host’s defences may offer a route to new pest-control strategies.

Vein, Eye Scans on Station as Next Crew Nears Launch

(From left) Expedition 65 crew members Pyotr Dubrov, Oleg Novitskiy and Mark Vande Hei, pose for a photo during Soyuz qualification exams in Moscow.

The Expedition 64 crew continued researching how microgravity affects biology aboard the International Space Station today. The orbital residents also conducted vein and eye checks and prepared for three new crew members due in early April.

NASA Flight Engineer Shannon Walker joined Russian cosmonauts Sergey Ryzhikov and Sergey Kud-Sverchkov for vein and eye scans on Thursday. Japan Aerospace Exploration Agency astronaut Soichi Noguchi led the effort scanning veins in the trio’s neck, clavicle and shoulder areas using the Ultrasound 2 device in the morning. In the afternoon, Noguchi examined Walker’s eyes using the orbiting lab’s optical coherence tomography gear.

Walker also assisted fellow Flight Engineer Kate Rubins of NASA setting up samples of tiny worms for viewing in a microscope. Rubins captured video of the microscopic worms wriggling around to learn how microgravity affects genetic expression and muscle function. Insights from the Micro-16 study may benefit human health on and off the Earth.

New Genetic Mutation Discovered in People with Schizophrenia

The research team, led by Todd Lencz, PhD, with Itsik Pe’er, PhD, Tom Maniatis, PhD, and Erin Flaherty, PhD, of Columbia University, carried out a genetic study identifying a single letter change in the DNA code in the PCDHA3 gene that is associated with schizophrenia. The affected gene makes a type of protein called a protocadherin, which generates a cell surface “barcode” required for neurons to recognize, and communicate with, other neurons. They found that the PCDHA3 variant blocks this normal protocadherin function.

The discovery was made possible by the special genetic characteristics of the samples studied by Lencz’s team—patients with schizophrenia and healthy volunteers drawn from the Ashkenazi Jewish population. The Ashkenazi Jewish population represents an important population for study based on its unique history. Just a few hundred individuals who migrated to Eastern Europe less than 1000 years ago are the ancestors of nearly 10 million Ashkenazi Jews today. This lineage, combined with a tradition of marriage within the community, has resulted in a more uniform genetic background in which to identify disease-related variants.

“In addition to our primary findings regarding PCDHA3 and related genes, we were able— due to the unique characteristics of the Ashkenazi population—to replicate several prior findings in schizophrenia despite relatively small sample sizes,” said Lencz, professor in the Institute of Behavioral Science at the Feinstein Institutes. “In our study, we demonstrated this population represents a smart, cost-effective strategy for identifying disease-related genes. Our findings allow us to zero in on a novel aspect of brain development and function in our quest to develop new treatments for schizophrenia.”

There are no autism-specific genes, just brain genes

It is well established that rare, damaging genetic variants with strong effects contribute to autism. Although individually rare, these variants are collectively common: Clinical genetic testing identifies them in at least 25 percent of autistic people. Studies of these variants have implicated more than 100 genes — and counting — in autism.

Identifying these genes is important — not only for clinical care, but also for advancing our understanding of the neural circuits and processes involved in autism or in its core traits. It creates the opportunity to develop therapies targeted to specific molecular diagnoses. And as we learn more about these genes and the consequences of variants that disrupt their function, we have the potential to better understand the mechanisms underlying cases of autism in which a definitive genetic diagnosis cannot yet be made.

But the genetic findings in people with autism are not unique; deleterious variants in the same genes are also implicated in other neurodevelopmental conditions, such as intellectual disability, epilepsy, attention deficit hyperactivity disorder and schizophrenia. Specific genes and variants do not map neatly onto categorical clinical diagnoses or the core cognitive and behavioral traits that define them. In fact, there is not yet a single example of a gene that, when mutated, increases the likelihood of autism but not of other neurodevelopmental conditions.

Liz Parrish goes deep into gene therapies at the HackMyAge Podcast by Zora (March 2021)

Long but annotated! Most important here is human data for specific treatments due out starting in May or June. And apparently they had a mouse study where they expected a paper due out already but other groups chimed in to help with more testing so there is a delay.

Liz Parrish, CEO of BioViva Science and patient zero of biological rejuvenation with gene therapies, is interviewed by Zora Benhamou on her fresh podcast “HackMyAge”.

During the conversation, Liz enters deep into the world of gene therapies, either to cure monogenic diseases, multifactorial genetic diseases, or the mother of all diseases: aging itself.

The conversation lasts for one hour and twenty minutes and has no waste. However, to go direct to certain themes use the following time marks:

0:00:00 Zora introduces the podcast: who is Liz Parrish and what the conversation will be about.

Continue reading “Liz Parrish goes deep into gene therapies at the HackMyAge Podcast by Zora (March 2021)” | >

Gene Therapy Using ‘Zinc Fingers’ May Help Treat Alzheimer’s Disease

Summary: A new genetic engineering strategy significantly reduces levels of tau in animal models of Alzheimer’s disease. The treatment, which involves a single injection, appears to have long-last effects.

Source: Mass General.

Researchers have used a genetic engineering strategy to dramatically reduce levels of tau–a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease–in an animal model of the condition.

New technology ‘retrains’ cells to repair damaged brain tissue in mice after stroke

The regeneration of damaged central nervous system (CNS) tissues is one of the biggest goals of regenerative medicine.

Most stroke victims don’t receive treatment fast enough to prevent brain damage. Scientists at The Ohio State University Wexner Medical Center, College of Engineering and College of Medicine have developed technology to “retrain” cells to help repair damaged brain tissue. It’s an advancement that may someday help patients regain speech, cognition and motor function, even when administered days after an ischemic stroke.

Engineering and medical researchers use a process created by Ohio State called tissue nanotransfection (TNT) to introduce genetic material into cells. This allows them to reprogram skin cells to become something different—in this case vascular cells—to help fix damaged tissue.

Study findings published online today in the journal Science Advances.

Civil liability for damages related to germline and embryo editing against the legal admissibility of gene editing

The development of gene therapy, in particular gene editing using the CRISPR-Cas9 method, has prompted a lively discussion around the world about how deeply you can interfere with the human genome. The creators of this method have turned to the world community, including lawyers, to undertake a public discussion of the implications that it can create (The National Academies of Sciences Engineering Medicine, 2015). The most important problem to be resolved in the future, in my opinion, will be the issue of establishing very clear legal principles of liability for damages resulting from the editing of genes in human embryos and reproductive cells. However, before this happens, it is necessary to show the possible legal problems that may arise and that will certainly appear in future legislative work in the world. Questions must be asked to which world legal experts will need to seek answers. The goal of this paper is to show the possible legal problems and ask questions related to the liability for damages resulting from the editing of genes in human embryos and reproductive cells that will be answered in the future.

Private law considerations will be based on Polish law, although it should be pointed out that the conclusions derived from them appear to be of universal nature for different legal systems. Despite the fact that legal considerations will refer to the regulation of Polish law, the subject of the analysis will also be the differences in the legal qualification of reproductive cells and embryos in other European legislations. It seems that nowhere in the world are there special regulations regarding the liability for damage related to the genetic editing of reproductive cells or embryos. Therefore, there is a need to present new challenges for classic private law institutions, such as legal abilities, torts, or liability for damages. Due to the lack of uniform European regulations and different conflicts of rights the subject of analysis will not be wrongful life and wrongful birth actions, but only claims of prenatal damage to a child.

The first major legal problem facing the international community is, of course, the question of the legal acceptability of the editing of genes of human reproductive cells and embryos (van Dijke et al., 2018). In this regard, it should be pointed out that despite the initial demand to ban such editing, over time, increasingly more scientists have pointed to the fact that it is not possible to maintain such a moratorium (Doudna and Sternberg, 2017). Jiankui’s presentation at the Second International Summit on Human Genome Editing on November 272018, showed that the introduction of a moratorium on genetic modifications of embryos in Europe, the condemnation of such research by a group of 120 of the greatest geneticists, even the Chinese regulations (Zhang and Lie, 2018) will not limit its conduct (Cyranoski and Ledford, 2018). Globalization of the medical market means that if any procedures are allowed on other continents, they will also become available to Europeans (Lunshof, 2016).

The origin of SARS-CoV-2 furin cleavage site remains a mystery

“The furin cleavage site consists of four amino acids PRRA, which are encoded by 12 inserted nucleotides in the S gene. A characteristic feature of this site is an arginine doublet. This insertion could have occurred by random insertion mutation, recombination or by laboratory insertion. The researchers say the possibility of random insertion is too low to explain the origin of this motif. Surprisingly, the CGGCGG codons encoding the two arginines of the doublet in SARS-CoV-2 are not found in any of the furin sites in other viral proteins expressed by a wide range of viruses. Even within the SARS-CoV-2, where arginine is encoded by six codons, only a minority of arginine residues are encoded by the CGG codon. Again, only two of the 42 arginines in the SARS-CoV-2 spike are encoded by this codon — and these are in the PRRA motif. For recombination to occur, there must be a donor, from another furin site and probably from another virus. In the absence of a known virus containing this arginine doublet encoded by the CGGCGG codons, the researchers discount the recombination theory as the mechanism underlying the emergence of PRRA in SARS-CoV-2.”

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has largely defied attempts to contain its spread by non-pharmaceutical interventions (NPIs). With the massive loss of life and economic damage, the only way out, in the absence of specific antiviral therapeutics, has been the development of vaccines to achieve population immunity.

A new study on the Preprints server discusses the origin of the furin cleavage site on the SARS-CoV-2 spike protein, which is responsible for the virus’s relatively high infectivity compared to relatives in the betacoronavirus subgenus.

COVID-19 Virtual Press conference transcript

Substantial transmission of SARS-CoV-2 infection occurred in the population of Wuhan in December 2019 with most cases reported in the second half of that month. Many early reported cases were associated with Huanan Market, indicating that it was one of the focus of the transmission. Nevertheless, transmission was also occurring elsewhere in Wuhan at the same time.

It is not possible on the basis of the current epidemiological information to determine how the SARS-CoV-2 was introduced into the Huanan Market. Substantial transmission of SARS-CoV-2 infection occurred among the population of Wuhan in December 2019.

While some of the early cases had an association with the Huanan Seafood Market, others were associated with other markets and other cases have no market association at all. It is likely that Huanan Seafood Market acted as a focus for transmission of the virus, but there are also transmissions appearing to have the occurrence elsewhere in Wuhan at the same time. This is our basic judgment. It is not possible on the basis of the current information to determine how SARS-CoV-2 was introduced into the Huanan Market.

The third part of my introduction will be the research of the animal environment group, the third group of our joint mission. Coronaviruses that phylogenetically relate to SARS-CoV-2 have been identified in different animals, including horseshoe bats and pangolins. Sampling of bats in Hubei Province, however, has failed to identify evidence of SARS-CoV-2-related viruses and sampling of wildlife in different places in China has so far failed to identify the presence of SARS-CoV-2.

Publicaciones de la organización mundial de la salud.

/* */